Esoteric Testing Market Size, Share & Trends Report

Esoteric Testing Market (2025 - 2030) Size, Share & Trends Analysis Report By Type (Oncology Testing, Infectious Disease Testing, Infectious Genetic Testing), By Technology, By End Use (Hospital-based Laboratories) By Region, And Segment Forecasts

Market Segmentation

Esoteric Testing Type Outlook (Revenue in USD Million, 2018 - 2030)
- Oncology testing
- Infectious disease testing
- Genetic testing
- Endocrinology testing
- Toxicology testing
- Neurology testing
- Others
Esoteric Testing Technology Outlook (Revenue in USD Million, 2018 - 2030)
- Chemiluminescence immunoassay
- Enzyme-linked immunosorbent assay
- Mass spectrometry
- Real time polymerase chain reaction
- Flow cytometry
- Others
Esoteric Testing End Use Outlook (Revenue in USD Million, 2018 - 2030)
- Hospital-based laboratories
- Independent and reference laboratories
- Other
Esoteric Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology testing
    - Infectious disease testing
    - Genetic testing
    - Endocrinology testing
    - Toxicology testing
    - Neurology testing
    - Others
  - North America Technology Outlook (Revenue in USD Million, 2018 - 2030)
    - Chemiluminescence immunoassay
    - Enzyme-linked immunosorbent assay
    - Mass spectrometry
    - Real time polymerase chain reaction
    - Flow cytometry
    - Others
  - North America End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospital-based laboratories
    - Independent and reference laboratories
    - Other
  - U.S.
    - U.S. Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - U.S. Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - U.S. End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Canada
    - Canada Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Canada Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Canada End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Mexico
    - Mexico Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Mexico Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Mexico End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
- Europe
  - Europe Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology testing
    - Infectious disease testing
    - Genetic testing
    - Endocrinology testing
    - Toxicology testing
    - Neurology testing
    - Others
  - Europe Technology Outlook (Revenue in USD Million, 2018 - 2030)
    - Chemiluminescence immunoassay
    - Enzyme-linked immunosorbent assay
    - Mass spectrometry
    - Real time polymerase chain reaction
    - Flow cytometry
    - Others
  - Europe End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospital-based laboratories
    - Independent and reference laboratories
    - Other
  - UK
    - UK Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - UK Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - UK End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Germany
    - Germany Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Germany Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Germany End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - France
    - France Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - France Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - France End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Italy
    - Italy Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Italy Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Italy End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Spain
    - Spain Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Spain Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Spain End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Denmark
    - Denmark Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Denmark Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Denmark End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Sweden
    - Sweden Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Sweden Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Sweden End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Norway
    - Norway Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Norway Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Norway End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
- Asia Pacific
  - Asia Pacific Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology testing
    - Infectious disease testing
    - Genetic testing
    - Endocrinology testing
    - Toxicology testing
    - Neurology testing
    - Others
  - Asia Pacific Technology Outlook (Revenue in USD Million, 2018 - 2030)
    - Chemiluminescence immunoassay
    - Enzyme-linked immunosorbent assay
    - Mass spectrometry
    - Real time polymerase chain reaction
    - Flow cytometry
    - Others
  - Asia Pacific End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospital-based laboratories
    - Independent and reference laboratories
    - Other
  - China
    - China Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - China Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - China End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Japan
    - Japan Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Japan Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Japan End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - India
    - India Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - India Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - India End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - South Korea
    - South Korea Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - South Korea Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - South Korea End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Australia
    - Australia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Australia Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Australia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Thailand
    - Thailand Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Thailand Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Thailand End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
- Latin America
  - Latin America Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology testing
    - Infectious disease testing
    - Genetic testing
    - Endocrinology testing
    - Toxicology testing
    - Neurology testing
    - Others
  - Latin America Technology Outlook (Revenue in USD Million, 2018 - 2030)
    - Chemiluminescence immunoassay
    - Enzyme-linked immunosorbent assay
    - Mass spectrometry
    - Real time polymerase chain reaction
    - Flow cytometry
    - Others
  - Latin America Pacific End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospital-based laboratories
    - Independent and reference laboratories
    - Other
  - Brazil
    - Brazil Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Brazil Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Brazil End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Argentina
    - Argentina Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Argentina Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Argentina End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
- Middle East & Africa (MEA)
  - Middle East & Africa (MEA) Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology testing
    - Infectious disease testing
    - Genetic testing
    - Endocrinology testing
    - Toxicology testing
    - Neurology testing
    - Others
  - Middle East & Africa (MEA) Technology Outlook (Revenue in USD Million, 2018 - 2030)
    - Chemiluminescence immunoassay
    - Enzyme-linked immunosorbent assay
    - Mass spectrometry
    - Real time polymerase chain reaction
    - Flow cytometry
    - Others
  - Middle East & Africa (MEA) End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospital-based laboratories
    - Independent and reference laboratories
    - Other
  - South Africa
    - South Africa Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - South Africa Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - South Africa End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Saudi Arabia
    - Saudi Arabia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Saudi Arabia Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Saudi Arabia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - UAE
    - UAE Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - UAE Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - UAE End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Kuwait
    - Kuwait Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Kuwait Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Kuwait End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments